Medical School

  • Emory University , 1999 , Atlanta , GA


  • Emory University School of Medicine , 2003 , Atlanta , GA


  • Aflac Cancer Center and Blood Disorders Service, Emory University School of Medicine , 2005 , Atlanta , GA


  • American Board of Pediatrics, Pediatric Hematology and Oncology


Publications powered by Harvard Catalyst Profiles

  1. Insights from integrating clinical and preclinical studies advance understanding of graft-versus-host disease. J Clin Invest. 2021 06 15; 131(12). View abstract
  2. Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers. Blood Adv. 2021 06 08; 5(11):2519-2522. View abstract
  3. Multiply restimulated human thymic regulatory T cells express distinct signature regulatory T-cell transcription factors without evidence of exhaustion. Cytotherapy. 2021 08; 23(8):704-714. View abstract
  4. Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses. Blood. 2021 02 25; 137(8):1090-1103. View abstract
  5. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. J Clin Oncol. 2021 06 10; 39(17):1865-1877. View abstract
  6. Measurement of leukocyte trafficking kinetics in macaques by serial intravascular staining. Sci Transl Med. 2021 01 13; 13(576). View abstract
  7. Spatiotemporal single-cell profiling reveals that invasive and tissue-resident memory donor CD8+ T cells drive gastrointestinal acute graft-versus-host disease. Sci Transl Med. 2021 01 13; 13(576). View abstract
  8. Creating an international network for science and clinical progress: democratizing dissemination of advances in global hematology. Blood Adv. 2021 01 12; 5(1):275-276. View abstract
  9. Current Concepts and Advances in Graft-Versus-Host Disease Immunology. Annu Rev Immunol. 2021 04 26; 39:19-49. View abstract
  10. Author Correction: Innovations present in the primate interneuron repertoire. Nature. 2020 Dec; 588(7837):E17. View abstract
  11. End the pain: Start with antiracism. Am J Hematol. 2021 01; 96(1):4-6. View abstract
  12. Robust expansion of HIV CAR T cells following antigen boosting in ART-suppressed nonhuman primates. Blood. 2020 10 08; 136(15):1722-1734. View abstract
  13. Isolation of a Highly Purified HSC-enriched CD34+CD90+CD45RA- Cell Subset for Allogeneic Transplantation in the Nonhuman Primate Large-animal Model. Transplant Direct. 2020 Aug; 6(8):e579. View abstract
  14. Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort. Blood Adv. 2020 06 09; 4(11):2536-2547. View abstract
  15. Single-Cell Analyses of Colon and Blood Reveal Distinct Immune Cell Signatures of Ulcerative Colitis and Crohn's Disease. Gastroenterology. 2020 08; 159(2):591-608.e10. View abstract
  16. IL-2 enhances ex vivo-expanded regulatory T-cell persistence after adoptive transfer. Blood Adv. 2020 04 28; 4(8):1594-1605. View abstract
  17. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. Cell. 2020 05 28; 181(5):1016-1035.e19. View abstract
  18. A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors. Pediatr Blood Cancer. 2020 04; 67(4):e28134. View abstract
  19. Characterization of natural killer cells expressing markers associated with maturity and cytotoxicity in children and young adults with sickle cell disease. Pediatr Blood Cancer. 2019 05; 66(5):e27601. View abstract
  20. Evidence for persistence of the SHIV reservoir early after MHC haploidentical hematopoietic stem cell transplantation. Nat Commun. 2018 10 25; 9(1):4438. View abstract
  21. CD28 blockade controls T cell activation to prevent graft-versus-host disease in primates. J Clin Invest. 2018 08 31; 128(9):3991-4007. View abstract
  22. Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. Blood. 2018 09 27; 132(13):1438-1451. View abstract
  23. Defining success with cellular therapeutics: the current landscape for clinical end point and toxicity analysis. Blood. 2018 06 14; 131(24):2630-2639. View abstract
  24. Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice. Mol Ther. 2018 06 06; 26(6):1423-1434. View abstract
  25. Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates. Cancer Discov. 2018 06; 8(6):750-763. View abstract
  26. Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant. Sci Transl Med. 2017 Sep 20; 9(408). View abstract
  27. In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines. Am J Transplant. 2017 Dec; 17(12):3098-3113. View abstract
  28. Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy. Immunol Rev. 2017 03; 276(1):192-212. View abstract
  29. A Canine Model of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017 Mar; 23(3):420-427. View abstract
  30. Preclinical Testing of Antihuman CD28 Fab' Antibody in a Novel Nonhuman Primate Small Animal Rodent Model of Xenogenic Graft-Versus-Host Disease. Transplantation. 2016 Dec; 100(12):2630-2639. View abstract
  31. Systems analysis uncovers inflammatory Th/Tc17-driven modules during acute GVHD in monkey and human T cells. Blood. 2016 11 24; 128(21):2568-2579. View abstract
  32. The Knife's Edge of Tolerance: Inducing Stable Multilineage Mixed Chimerism but With a Significant Risk of CMV Reactivation and Disease in Rhesus Macaques. Am J Transplant. 2017 03; 17(3):657-670. View abstract
  33. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. J Clin Invest. 2016 07 01; 126(7):2642-60. View abstract
  34. Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention. Sci Transl Med. 2015 Nov 25; 7(315):315ra191. View abstract
  35. Immunophenotypic parameters and RBC alloimmunization in children with sickle cell disease on chronic transfusion. Am J Hematol. 2015 Dec; 90(12):1135-41. View abstract
  36. Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant Diseases. Biol Blood Marrow Transplant. 2015 Oct; 21(10):1845-52. View abstract
  37. Red blood cell transfusions are associated with HLA class I but not H-Y alloantibodies in children with sickle cell disease. Br J Haematol. 2015 Jul; 170(2):247-56. View abstract
  38. CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRß repertoire. Blood. 2015 Jun 18; 125(25):3835-50. View abstract
  39. Immune parameter analysis of children with sickle cell disease on hydroxycarbamide or chronic transfusion therapy. Br J Haematol. 2015 May; 169(4):574-83. View abstract
  40. Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. Am J Transplant. 2014 Dec; 14(12):2691-703. View abstract
  41. Persistence of virus reservoirs in ART-treated SHIV-infected rhesus macaques after autologous hematopoietic stem cell transplant. PLoS Pathog. 2014 Sep; 10(9):e1004406. View abstract
  42. Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors. Am J Transplant. 2014 May; 14(5):1142-51. View abstract
  43. CD8-predominant T-cell CNS infiltration accompanies GVHD in primates and is improved with immunoprophylaxis. Blood. 2014 Mar 20; 123(12):1967-9. View abstract
  44. In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial. Biol Blood Marrow Transplant. 2013 Nov; 19(11):1638-49. View abstract
  45. Pluripotent stem cells: immune to the immune system? Sci Transl Med. 2012 Dec 12; 4(164):164ps25. View abstract
  46. Cooking up tolerance: has a new recipe been created? Am J Transplant. 2012 Jul; 12(7):1667-9. View abstract
  47. Evidence for kidney rejection after combined bone marrow and renal transplantation despite ongoing whole-blood chimerism in rhesus macaques. Am J Transplant. 2012 Jul; 12(7):1755-64. View abstract
  48. Regulatory T cells exhibit decreased proliferation but enhanced suppression after pulsing with sirolimus. Am J Transplant. 2012 Jun; 12(6):1441-57. View abstract
  49. Nonhuman primate transplant models finally evolve: detailed immunogenetic analysis creates new models and strengthens the old. Am J Transplant. 2012 Apr; 12(4):812-9. View abstract
  50. Significant mobilization of both conventional and regulatory T cells with AMD3100. Blood. 2011 Dec 15; 118(25):6580-90. View abstract
  51. CD40 blockade combines with CTLA4Ig and sirolimus to produce mixed chimerism in an MHC-defined rhesus macaque transplant model. Am J Transplant. 2012 Jan; 12(1):115-25. View abstract
  52. Alloimmunization to transfused HOD red blood cells is not increased in mice with sickle cell disease. Transfusion. 2012 Feb; 52(2):231-40. View abstract
  53. An MHC-defined primate model reveals significant rejection of bone marrow after mixed chimerism induction despite full MHC matching. Am J Transplant. 2010 Nov; 10(11):2396-409. View abstract
  54. GVHD after haploidentical transplantation: a novel, MHC-defined rhesus macaque model identifies CD28- CD8+ T cells as a reservoir of breakthrough T-cell proliferation during costimulation blockade and sirolimus-based immunosuppression. Blood. 2010 Dec 09; 116(24):5403-18. View abstract
  55. Expanded nonhuman primate tregs exhibit a unique gene expression signature and potently downregulate alloimmune responses. Am J Transplant. 2008 Nov; 8(11):2252-64. View abstract
  56. Expansion of effector memory TCR Vbeta4+ CD8+ T cells is associated with latent infection-mediated resistance to transplantation tolerance. J Immunol. 2008 Mar 01; 180(5):3190-200. View abstract
  57. Induction of chimerism in rhesus macaques through stem cell transplant and costimulation blockade-based immunosuppression. Am J Transplant. 2007 Feb; 7(2):320-35. View abstract
  58. Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease. Blood. 2003 Dec 15; 102(13):4582-93. View abstract
  59. Comparison of mechanisms of anemia in mice with sickle cell disease and beta-thalassemia: peripheral destruction, ineffective erythropoiesis, and phospholipid scramblase-mediated phosphatidylserine exposure. Exp Hematol. 2002 May; 30(5):394-402. View abstract
  60. A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation. Blood. 2002 Mar 01; 99(5):1840-9. View abstract
  61. Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression. J Immunol. 2001 Jul 15; 167(2):1103-11. View abstract